<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176277</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-7475-01</org_study_id>
    <nct_id>NCT03176277</nct_id>
  </id_info>
  <brief_title>A Study of ONO-7475 in Patients With Acute Leukemias</brief_title>
  <official_title>A Phase I Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and maximum tolerated dose of ONO-7475 in patients with
      relapsed or refractory acute leukemia or relapsed or refractory myelodysplastic syndromes,
      and evaluate the efficacy of ONO-7475 in patients with newly diagnosed AML
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">March 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of (serious) Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant ophthalmology examinations</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant electrocardiogram (ECG)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by the incidence, nature, and severity of (serious) Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of recommended pharmacological dose</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by the Plasma inhibitory activity (PIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the plasma area under the curve (day 1 and 28) of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the plasma decay half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough)</measure>
    <time_frame>Cycle 1 predose Day 7 and Day 15/ 7 days after the last dosing of ONO-7475 at investigator's discretion (PK follow-up)</time_frame>
    <description>Assessment of the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax) - - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the plasma area under the curve of ONO-7475</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the plasma decay half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of ONO-7475</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment of the pharmacodynamic activity of ONO-7475 as assessed by a PIA assay (pAxl/pMer inhibition).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CR/CRi/MLFS/PR for AML, CR/CRi for ALL, CR/Marrow CR/PR for MDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from CR/CRi/MLFS/PR to disease recurrence for AML, CR/CRi to relapse/disease progression for ALL and CR/Marrow CR/PR to relapse after CR/PR or disease progression for MDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from date of first study treatment to disease recurrence/treatment failure or death for AML, to relapse/disease progression/refractory or death for ALL and to relapse after CR/PR or disease progression or failure or death for MDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response without minimal residual disease (MRD) AML &amp; ALL</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by flow cytometry for patients who achieve CR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>ONO-7475: dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Successive dose escalation cohorts to determine MTD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7475</intervention_name>
    <description>ONO-7475 tablets</description>
    <arm_group_label>ONO-7475: dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged â‰¥18 years at time of screening

          2. Written informed consent by the patient (or legal representative) prior to admission
             to this study. In addition any locally required authorization (Health Insurance
             Portability and Accountability Act in the USA [HIPAA], obtained from the patient prior
             to performing any protocol-related procedures, including screening evaluations.

          3. Adequate renal and hepatic function defined as:

               -  Total bilirubin within 1.5 x ULN, except those with Gilberts syndrome for whom
                  this must be &lt;3 x ULN

               -  AST(SGOT) and ALT(SGPT) &lt;2.5 x ULN

               -  Calculated Creatinine clearance&gt;/= 45ml/min

               -  Serum Albumin &gt;2.5g/dL For any patient laboratory values outside the ranges
                  outlined above that are considered due to the patient's underlying disease (AML,
                  MDS or ALL), the patient may be enrolled into the study following consultation
                  between the Investigator and the Sponsor's Medical Officer if the patient is
                  likely to benefit from receiving ONO-7475 (based on the Investigator's
                  assessment)

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 as assessed during
             the screening period and then again anytime during the 2-day period immediately
             preceding the start of ONO-7475 dosing.

          5. Life expectancy of at least 3 months

          6. Sexually active female patients of childbearing potential and sexually active male
             patients must agree to use an effective method of birth control (e.g., barrier methods
             with spermicides, oral or parenteral contraceptives and/or intrauterine devices)
             during the entire duration of the study and for 4 months after final administration of
             study drug. Note that sterility in female patients must be confirmed in the patients'
             medical records and be defined as any of the following: surgical hysterectomy with
             bilateral oophorectomy, bilateral tubular ligation, natural menopause with last menses
             &gt;1 year ago; radiation induced oophorectomy with last menses &gt;1 year ago; chemotherapy
             induced menopause with last menses &gt;1 year ago.

          7. Male patients must use a condom from the time of the first administration of ONO-7475
             until 4 months following administration of the last dose.

        8. Diagnosis of AML or MDS according to WHO criteria 2016.

        9. Either criterion is met:

          1. Relapsed or refractory AML patients with at least 5% blasts by bone marrow biopsy or
             aspirate, or at least 1% blasts in peripheral blood, not likely to benefit from
             standard salvage chemotherapy.

          2. Relapsed or refractory MDS patients who are either not eligible for (or unlikely to
             benefit from) other forms of therapy including hematopoietic stem cell
             transplantation, according to the treating physician/investigator

             10. All patients must have received at least one previous line or therapy.

             Exclusion Criteria:

               1. Patients with active Central Nervous System (CNSL) Leukemia

               2. QTcF prolongation defined as a QTcF interval &gt;470 msec or other significant ECG
                  abnormalities including 2nd degree (type II) or 3rd degree AV block or
                  bradycardia (ventricular rate &lt;50 beats/min).

               3. Clinically significant liver disease, including active viral or other hepatitis,
                  current alcohol abuse, or severe cirrhosis

               4. HIV/active Hepatitis B or C infection

               5. Retinal disease (e.g. retinitis pigmentosa including Mertk mutations), retinal
                  hemorrhage or any disorder which may inhibit follow up for retinal toxicity

               6. Serious intercurrent medical or psychiatric illness that will prevent
                  participation or compliance with study procedures, including serious active
                  infection

               7. Acute promyelocytic leukemia (FAB M3 classification)

               8. Patients not recovered to Grade 1 or stabilized from the effects (excluding
                  alopecia) of any prior therapy for their malignancies

               9. Concurrent treatment with other investigational drugs.

              10. Daily requirement for corticosteroids â‰¥ prednisone 10 mg/day or equivalent.

              11. Prior hematopoietic stem cell transplantation within 12 weeks of the first dose
                  of study treatment or ongoing immunosuppressive therapy for graft versus host
                  disease

              12. Participation in another clinical trial with any investigational drug within 14
                  days or with any licensed drug within five half-lives, prior to the first
                  ONO-7475 dosing.

              13. Prior AML, MDS or ALL therapy (non-experimental) within 14 days or five
                  half-lives whichever is longer, prior to the first dose of ONO-7475 (except those
                  permitted in the protocol) and no residual toxicity from the prior therapy
                  hindering of the ONO-7475 dosing.

              14. Prior radiotherapy within 21 days of screening, with the exception of localized
                  palliative radiotherapy.

              15. Patients undergoing current treatments for other cancers

              16. Pregnant or lactating women

              17. Proliferative disease (WBC &gt; 30 x 109 /L) confirmed prior to first dose of
                  ONO-7475

              18. Active malignancy, other than AML, or MDS (Parts A), AML (Part B) or ALL (Part
                  C), requiring systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ONO Pharma UK Ltd</last_name>
    <role>Study Director</role>
    <affiliation>Drug Development Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - Hollins Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myeloid, Acute</keyword>
  <keyword>MER</keyword>
  <keyword>MERTK</keyword>
  <keyword>TYRO3</keyword>
  <keyword>AXL</keyword>
  <keyword>AML</keyword>
  <keyword>de novo AML</keyword>
  <keyword>Relapsed/ Refractory AML</keyword>
  <keyword>TAM</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Relapsed/ Refractory MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

